← Leaderboards
Robert Babak Faryabi
University Of Pennsylvania
$4,597,941
Attributed
$9,225,300
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.6M · FY2020–25$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,225,300 · 4
By mechanism
U01$5,505,755 · 2
R01$3,719,545 · 2
Top collaborators
- Alvin Carter Powers4 shared
- Mark A Atkinson3 shared
- Rita Bottino3 shared
- Marcela Brissova3 shared
- Anna Louise Gloyn3 shared
- Dirk Homann3 shared
- Seung K Kim3 shared
- Patrick Macdonald3 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Stephen G Emerson$28,932,839
- Daniel James Rader$77,348,993
- Daniel Patrick Kelly$33,087,106
- Lewis A Chodosh$38,386,361
- Charles P Emerson$35,198,488
Others in their field
Other Emerging Leaders on “Programs”
- Leonard Freedman · Leidos Biomedical Research, Inc.$994,984,644
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$348,328,584
- Lynn Briscoe · Leidos Biomedical Research, Inc.$312,382,073
- Chanza Baytop · Westat, Inc.$271,217,917
Research focus
ProgramsResolutionPositioning AttributeTargeted TreatmentCellsProteinsGenesGene ExpressionEpigenetic ProcessFrequenciesHomeostasisDrug ResistanceMolecularBindingGenome EditingComplexKineticsGene ActivationFunctional GenomicsClustered Regularly Interspaced Short Palindromic RepeatsGenomeGenetic TranscriptionEnhancersChromatin
Grant awards (14)
Human Pancreas Analysis Program for Type 2 Diabetes (HPAP-T2D)$2,999,756
U01 · FY2025 · DK
Epigenetic Mechanisms Underpinning Mantle Cell Lymphoma Sensitivity and Resistance to Notch Inhibitors$418,291
R01 · FY2025 · CA · contact PI
Notch-driven Epigenetic Program of MYC and CCND1 in Triple-Negative Breast Cancer$231,308
R01 · FY2025 · CA · contact PI
Human Pancreas Analysis Program-T2D$1,055,999
U01 · FY2024 · DK
Epigenetic Mechanisms Underpinning Mantle Cell Lymphoma Sensitivity and Resistance to Notch Inhibitors$396,850
R01 · FY2024 · CA · contact PI
Notch-driven Epigenetic Program of MYC and CCND1 in Triple-Negative Breast Cancer$394,246
R01 · FY2024 · CA · contact PI
Human Pancreas Analysis Program-T2D$1,100,000
U01 · FY2023 · DK
Epigenetic Mechanisms Underpinning Mantle Cell Lymphoma Sensitivity and Resistance to Notch Inhibitors$408,858
R01 · FY2023 · CA · contact PI
Notch-driven Epigenetic Program of MYC and CCND1 in Triple-Negative Breast Cancer$407,447
R01 · FY2023 · CA · contact PI
Human Pancreas Analysis Program-T2D$350,000
U01 · FY2023 · DK
Epigenetic Mechanisms Underpinning Mantle Cell Lymphoma Sensitivity and Resistance to Notch Inhibitors$420,829
R01 · FY2022 · CA · contact PI
Notch-driven Epigenetic Program of MYC and CCND1 in Triple-Negative Breast Cancer$420,652
R01 · FY2022 · CA · contact PI
Notch-driven Epigenetic Program of MYC and CCND1 in Triple-Negative Breast Cancer$193,484
R01 · FY2021 · CA · contact PI
Notch-driven Epigenetic Program of MYC and CCND1 in Triple-Negative Breast Cancer$427,580
R01 · FY2020 · CA · contact PI